Gland Pharma Limited

rs 25

LIMITED October 26, 2022 BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245 National Stock Exchange of India Limi

3%

isruption Revenue from Operations (INR Mn) EBITDA (1) / EBITDA Margin (2) (INR Mn / %) 10,805 - 3% 8,569 10,444 22,344 19,013 4,278 3,443 3,625 38% 37% 33% 9,259 39% 7,068 35% Q2 FY22

38%

/ EBITDA Margin (2) (INR Mn / %) 10,805 - 3% 8,569 10,444 22,344 19,013 4,278 3,443 3,625 38% 37% 33% 9,259 39% 7,068 35% Q2 FY22 Q1 FY23 Q2 FY23 6M FY22 6M FY23 Q2 FY22 Q1 FY23 Q

37%

TDA Margin (2) (INR Mn / %) 10,805 - 3% 8,569 10,444 22,344 19,013 4,278 3,443 3,625 38% 37% 33% 9,259 39% 7,068 35% Q2 FY22 Q1 FY23 Q2 FY23 6M FY22 6M FY23 Q2 FY22 Q1 FY23 Q2 FY2

33%

argin (2) (INR Mn / %) 10,805 - 3% 8,569 10,444 22,344 19,013 4,278 3,443 3,625 38% 37% 33% 9,259 39% 7,068 35% Q2 FY22 Q1 FY23 Q2 FY23 6M FY22 6M FY23 Q2 FY22 Q1 FY23 Q2 FY23 6M

39%

NR Mn / %) 10,805 - 3% 8,569 10,444 22,344 19,013 4,278 3,443 3,625 38% 37% 33% 9,259 39% 7,068 35% Q2 FY22 Q1 FY23 Q2 FY23 6M FY22 6M FY23 Q2 FY22 Q1 FY23 Q2 FY23 6M FY22 6M FY

35%

10,805 - 3% 8,569 10,444 22,344 19,013 4,278 3,443 3,625 38% 37% 33% 9,259 39% 7,068 35% Q2 FY22 Q1 FY23 Q2 FY23 6M FY22 6M FY23 Q2 FY22 Q1 FY23 Q2 FY23 6M FY22 6M FY23 PBT / PA

25%

argin (3) (INR Mn / %) R&D Expenses / (R&D % of Revenue) (INR Mn / %) 4,007 3,021 3,085 2,292 25% 27% 29% 3,241 2,412 22% 28% 8,725 6,527 6,326 28% 4,704 23% 5.3% 578 2.0% 216 3.3%

27%

(3) (INR Mn / %) R&D Expenses / (R&D % of Revenue) (INR Mn / %) 4,007 3,021 3,085 2,292 25% 27% 29% 3,241 2,412 22% 28% 8,725 6,527 6,326 28% 4,704 23% 5.3% 578 2.0% 216 3.3% 362

29%

(INR Mn / %) R&D Expenses / (R&D % of Revenue) (INR Mn / %) 4,007 3,021 3,085 2,292 25% 27% 29% 3,241 2,412 22% 28% 8,725 6,527 6,326 28% 4,704 23% 5.3% 578 2.0% 216 3.3% 362 4.0

22%

xpenses / (R&D % of Revenue) (INR Mn / %) 4,007 3,021 3,085 2,292 25% 27% 29% 3,241 2,412 22% 28% 8,725 6,527 6,326 28% 4,704 23% 5.3% 578 2.0% 216 3.3% 362 4.0% 0.2% 414 20 3.

28%

es / (R&D % of Revenue) (INR Mn / %) 4,007 3,021 3,085 2,292 25% 27% 29% 3,241 2,412 22% 28% 8,725 6,527 6,326 28% 4,704 23% 5.3% 578 2.0% 216 3.3% 362 4.0% 0.2% 414 20 3.8% 3

Corporate Office

2

Regd. Office

1

Regd. Office

Survey N o . 143-148, 1 5 0 & 151, N e a r Gandimaisamma ‘X’ Roads Survey N o . 143-148, 1 5 0 & 151, N e a r Gandimaisamma ‘X’ Roads D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal D.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Medchal-Malkajgiri District, Hyderabad 500043, Telangana, Medchal-Malkajgiri District, Hyderabad 500043, Telangana, Tel: +91-40-30510999 Fax: +91-40-30510800 Tel: +91-40-30510999 Fax: +91-40-30510800 India India

Corporate Office

Plot N o . 11 & 84, T S I I C Phase: I V Plot N o . 11 & 84, T S I I C Phase: I V Pashamylaram (V), Patancheru (M), Sangareddy District Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India Hyderabad 502307, Telangana, India Tel: +91-8455-699999 Tel: +91-8455-699999 CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com Gland Pharma Limited Financial Results Q2’FY23 26th October 2022 Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. This presentation may include certain “forward looki

Corporate Office

Gland Pharma Limited Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India 543245 GLAND GLAND:IN 11